Skip to main content
Felicity Thomas on Muck Rack

Felicity Thomas

(She/Her)
  • Associate Director of Editorial and Content, Orientation Marketing
Cheshire, United Kingdom
As seen in: Color Research & Application, Wiley Online Library, Taylor & Francis Online, NewsBreak, POPSUGAR Australia, PA Consulting, Drug Solutions, Pharmaceutical Technology, BioPharm International, Pharmaceutical Technology MX and
Covers:  Drug Development, Drug Manufacturing, Outsourcing, Quality/Regulations, Analytics, Biopharmaceuticals, Advanced Therapies, Formulation, DSP, USP, Business, Clinical Trials
Editor, journalist, dabbler in IT sales support and baking, netball player and rugby union enthusiast. Mainly a mum.

Get in touch with Felicity

Contact Felicity, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Felicity Thomas’s Biography

Read Full Bio →

Highly experienced in pharmaceutical media and a specialist in scientific B2B publishing, I have previously held senior editorial positions at leading industry publications including LCGC Europe, Ophthalmology Times Europe, EPM Magazine, and most recently, Pharmaceutical Technology and BioPharm International. Over the course of my 20-year career, I have successfully led editorial strategy and operations for leading global publishers, establishing myself as a respected leader and influential voi…

Articles

Disrupting the Bioprocessing Footprint

|
By Felicity Thomas
| The Pharma Navigator
The biopharmaceutical industry is moving away from the traditional blockbuster drug model, where facilities manufactured vast quantities of a single product, toward more personalized, highly targeted therapies and complex bioconjugates. As a result of this shift, strategies around capacity planning, facility design, and industrialization are changing.
Open in Who Shared Issue with article?

BIO 2026: Bridging the Complexity Gap

|
By Felicity Thomas
| The Pharma Navigator
Scaling a drug candidate from benchtop discovery to standard multi-kilogram GMP batches represents an exponential escalation in complexity. For advanced nanomedicines and specialized drug conjugates, this transition is particularly treacherous. Traditional small-molecule approaches fail to accommodate the intricate multi-component assemblies required to keep these modern formulations stable and efficacious “Scaling targeted nanomedicines and drug conjugates is still hard...
Open in Who Shared Issue with article?

BIO 2026: Beyond the DNA Blueprint

|
By Felicity Thomas
| The Pharma Navigator
“Historically, genomics was the first omic discipline to achieve large-scale standardization,” specifies Karolina Žukauskienė, Scientific Project Manager at VUGENE — a specialist in multi-omics data analysis and interpretation. That standardization afforded a dramatic reduction in cost of drug discovery and allowed companies to mature their pipelines more rapidly, she notes. “Naturally, the industry focused on extracting as much value as possible from DNA-based information,” Žukauskienė continues.
Open in Who Shared Issue with article?
See all 425 licensed articles (770 Total)